
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics is facing challenges with the discontinuation of its Pociredir program for sickle cell disease due to FDA feedback and concerns around potential risks. However, the company has a strong pipeline of clinical-stage and pre-clinical programs for rare genetic diseases, which could potentially lead to future value creation through strategic alternatives and cost-cutting initiatives. Risks to the company's current outlook include possible setbacks in business development transactions and potential dilution risks in the face of sustained operating expenses.
Bears say
Fulcrum Therapeutics is facing major challenges with their primary product candidate, pociredir, being discontinued due to concerns about the risk of secondary malignancies. This decision by the FDA has greatly impacted the company's future plans and pipeline, forcing them to explore strategic alternatives and undergo restructuring. While the company has a strong cash position, there is limited visibility on future value creation opportunities, and thus a cautious stance is warranted at this time. Additionally, there are various risks to the company, including clinical, regulatory, and financial, which may negatively or positively impact the stock. As a result, a negative outlook is warranted for Fulcrum Therapeutics.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares